Bile Acid Metabolism Subtyping Reveals Prognostic Markers in Colorectal Cancer

Study Background and Research Question

Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide, with over two million new cases and nearly one million deaths annually, according to recent global statistics. Despite the advent of immune checkpoint inhibitors (ICIs) transforming treatment for patients with advanced and microsatellite instability-high (MSI-H) CRC, the challenge of primary resistance means only a subset of patients derive benefit. The tumor immune microenvironment (TIME) is increasingly recognized as a key determinant of both prognosis and therapeutic response, but its molecular underpinnings remain incompletely understood.

Bile acids, beyond their canonical role in lipid metabolism, have emerged as signaling molecules influencing cancer development, notably in CRC. Dysregulated bile acid metabolism has been linked to tumor invasion, proliferation, and immune modulation, yet the precise mechanisms by which bile acid metabolic states influence the TIME and patient outcomes have been insufficiently characterized. Against this background, Feng et al. (2026) posed a central research question: Can molecular subtypes of CRC, classified by bile acid metabolism, reveal immune dysfunction markers and prognostic indicators relevant to clinical outcomes and immunotherapy response? (reference study).

Key Innovation from the Reference Study

The principal innovation of this study is the integration of transcriptomic, clinical, and immunological data to define CRC molecular subtypes based on bile acid metabolism. By employing unsupervised consensus clustering of The Cancer Genome Atlas-Colon Adenocarcinoma (TCGA-COAD) cohort, the authors systematically classified CRC patients into bile acid metabolic subgroups. This approach permitted direct comparison of survival outcomes, immune cell infiltration, and gene expression patterns, allowing the discovery of three critical genes—CLCA1, UGT2A3, and ZG16—as robust markers of immune dysfunction and prognosis. This integrative methodology bridges metabolic and immunological axes, providing a framework for TIME-driven biomarker discovery and therapeutic stratification in CRC.

Methods and Experimental Design Insights

The study's methodology centers on the analysis of large-scale transcriptome and clinical datasets. Specifically, the authors utilized the TCGA-COAD cohort to perform unsupervised consensus clustering based on bile acid metabolism-related gene sets. Patients were assigned to distinct metabolic subtypes ("bile-low" and "bile-high") for comparative analyses.

• Immune Profiling: Immune cell infiltration levels were estimated using established bioinformatic pipelines, focusing particularly on CD8+ T cell and M1 macrophage populations.
• Differential Expression: Differentially expressed genes between subtypes were identified, followed by construction of a protein–protein interaction (PPI) network.
• Hub Gene Identification: Cox proportional hazards regression was used to pinpoint genes with prognostic significance.
• Validation: The expression of hub genes was validated in the Gene Expression Omnibus (GEO) cohort and in independent clinical samples.

Survival analyses and correlation with immune dysfunction (using the TIDE score) further substantiated the clinical relevance of identified markers. The robustness of the findings was enhanced by multi-cohort validation, strengthening the translational potential of the results (related article).

Protocol Parameters

• Bile acid metabolic profiling: Gene expression quantification from frozen CRC tissue; normalization using standard transcriptomic workflows prior to clustering.
• Immune infiltration estimation: Bioinformatic deconvolution (e.g., CIBERSORT) on normalized RNA-seq data to assess immune cell fractions.
• Hub gene validation: qPCR on independent patient samples; primer design for CLCA1, UGT2A3, ZG16 targeting exonic regions with minimal gDNA overlap to avoid contamination artifacts.
• Survival analysis: Stratification by hub gene expression (high vs low) and bile acid subtype; log-rank testing for overall survival differences.

Core Findings and Why They Matter

The study revealed that the "bile-low" CRC subtype exhibited a significantly reduced overall survival (OS) compared to "bile-high" (p = 0.0049). Notably, this group also demonstrated higher infiltration of CD8+ T cells (p < 0.05) and M1 macrophages (p < 0.01), suggesting paradoxical immune activation in a subgroup with poor prognosis. Among the differentially expressed genes, CLCA1, UGT2A3, and ZG16 were consistently downregulated in tumor tissue across TCGA, GEO, and independent clinical cohorts.

Survival analyses identified high CLCA1 expression as a significant predictor of favorable OS (p < 0.001), whereas UGT2A3 and ZG16 did not reach individual statistical significance. Importantly, all three genes were negatively correlated with the TIDE score (a surrogate for immune dysfunction and likely resistance to ICIs), with CLCA1 showing the strongest association (R = −0.24, p < 0.001). These findings suggest that bile acid metabolic state, as captured by these markers, may modulate the TIME and affect both prognosis and immunotherapy responsiveness (reference).

Comparison with Existing Internal Articles

The findings of Feng et al. build upon—and advance—the molecular subtyping framework discussed in previous internal resources. For example, "Bile Acid Metabolism Subtyping Reveals CRC Prognostic Markers" provides an overview of the link between bile acid metabolic state and immune dysfunction, while "HyperScript III RT SuperMix: Next-Gen cDNA Synthesis for Decoding CRC Immune Markers" addresses technical barriers in quantifying these markers, such as the need for high-fidelity cDNA synthesis from low-input or high-GC RNA templates. The synergy between biomarker discovery and robust gene expression quantification is further illustrated in internal workflow articles, which highlight the importance of eliminating genomic DNA contamination and optimizing reverse transcription efficiency for reproducible qPCR-based gene expression analysis.

Limitations and Transferability

While the integrative approach and multi-cohort validation strengthen the study's findings, some limitations must be acknowledged:

• Causality: The relationship between bile acid metabolism and immune dysfunction is correlative; mechanistic studies are needed to determine causation.
• Cohort Diversity: Most transcriptomic data derive from TCGA and GEO, which may not fully represent global population heterogeneity.
• Therapeutic Translation: Although the study links bile acid metabolism, gene expression, and immune response, direct implications for ICI selection or patient stratification remain to be prospectively validated.

Transferability to other cancer types or non-tumor settings is not established, and the prognostic value of UGT2A3 and ZG16, while suggestive, did not reach statistical significance individually.

Research Support Resources

Accurate gene expression analysis, particularly for low-abundance or high-GC content markers such as CLCA1, UGT2A3, and ZG16, is critical for translational CRC research. For workflows requiring reliable reverse transcription of low-concentration RNA and removal of genomic DNA contamination prior to qPCR, researchers may consider HyperScript™ III RT SuperMix for qPCR (with gDNA wiper) (SKU K1585). This reagent incorporates a third-generation reverse transcriptase with enhanced affinity, thermal stability, and fidelity, supporting robust cDNA synthesis even from challenging RNA templates. The inclusion of a gDNA wiper mix ensures accurate downstream qPCR, which is essential for reproducible gene expression analysis by qPCR in biomarker validation studies. Additional details on workflow optimization can be found in the related internal article.